edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Recce Pharmaceuticals
Recce Pharmaceuticals is developing novel, broad-spectrum synthetic polymer anti-infective drugs for the treatment of several infectious diseases, including sepsis, burn wound infections, urinary tract infections/urosepsis and diabetic foot infections.
Recce Pharmaceuticals — 6 videos in collection
Recce Pharmaceuticals (ASX: RCE) is a clinical-stage pharmaceutical company headquartered in New South Wales, Australia. It is a developing a new class of synthetic anti-infectives with novel mechanisms of action suited for treating multi-drug resistant bacteria and emerging viral pathogens. Recce’s lead candidate, RECCE 327, is being investigated for the treatment of sepsis and burn wound infections.
In this video, James Graham, Recce’s chief executive officer, explains what sets Recce apart from other antibiotic developers.
Get access to the very latest content matched to your personal investment style.